
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Keywords: Buparlisib; Fulvestrant; Hormone receptor-positive breast cancer; Overall survival; PIK3CA; ctDNA;